Status:
RECRUITING
Blood-based Biomarkers for Diagnosis of Alzheimer's
Lead Sponsor:
Helse Stavanger HF
Collaborating Sponsors:
Sahlgrenska University Hospital
Conditions:
Dementia Alzheimers
Eligibility:
All Genders
40-100 years
Phase:
NA
Brief Summary
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, ...
Detailed Description
A correct diagnosis of dementia is important in order to provide the patient and relatives with right information, and to give adequate treatment and support, but also to improve research and further ...
Eligibility Criteria
Inclusion
- Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening
Exclusion
- Lack of capacity for consent as judged by the GP.
- Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.
- Patients not wanting to be referred to the memory outpatient clinic.
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05187819
Start Date
June 1 2023
End Date
December 31 2029
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stavanger University Hospital
Stavanger, Norway, 4068